XXII Stock Risk & Deep Value Analysis

22nd Century Group Inc

Consumer Defensive • Tobacco

DVR Score

1.5

out of 10

Distressed

What You Need to Know About XXII Stock

We analyzed 22nd Century Group Inc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran XXII through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.

Updated Jun 2, 2026•Run Fresh Analysis →•

XXII Risk Analysis & Red Flags

What Could Go Wrong

The company's primary risk is its inability to generate positive operating cash flow, which could exhaust its remaining cash reserves of $9.545M within the next 2-3 quarters if Q1 2026's operating loss of $3.039M persists. This would lead to a significant risk of further dilution of common equity or, in the worst case, liquidation without generating value for common shareholders.

Risk Matrix

Overall

Aggressive

Financial

High

Market

Medium

Competitive

Medium

Execution

High

Regulatory

Medium

Red Flags

⚠
Q1 2026 reported gross loss of $0.636 million and significant operating/net losses, indicating fundamental business unprofitability.
⚠
Revenue declined by 31.1% YoY in Q1 2026, demonstrating an inability to capitalize on market opportunities despite regulatory advantage.
⚠
Previous Chapter 11 bankruptcy filing (Nov 2023) and delisting (Mar 2024), indicating severe financial distress and governance issues.
⚠
Common equity is subordinated by prior preferred stock financing, limiting potential upside for current common shareholders.
⚠
Market cap is reported as $0.00B (effectively negligible), implying that the market assigns extremely low value to common equity.

Upcoming Risk Events

📅
Q2 2026 earnings report (estimated early-August 2026): Further YoY revenue decline (>15%) or continued increase in operating losses and cash burn.
📅
Failure to secure additional financing (next 6-12 months): Continued significant cash burn without new capital could lead to further dilution or insolvency, given current cash balance of $9.545M and Q1 operating loss of $3.039M.

When to Reconsider

🚪
Quarterly cash and cash equivalents drop below $5.0 million, signaling critical liquidity issues.
🚪
Announcement of further significant common stock dilution or another debt financing round that further subordinates equity.
🚪
Consecutive quarters showing increasing YoY revenue decline (e.g., >15% further decline in Q2 2026).

Unlock XXII Risk Analysis & Red Flags

Create a free account to see the full analysis

What Does 22nd Century Group Inc (XXII) Do?

Market Cap

$2.43M

Sector

Consumer Defensive

Industry

Tobacco

Employees

22nd Century Group, Inc., a tobacco products company, manufactures, distributes, and sells proprietary new reduced nicotine tobacco products in the United States. The company offers reduced nicotine content tobacco and very low nicotine combustible cigarette products. It also provides contract manufacturing services for conventional combustible tobacco products for third-party brands, as well as turnkey contract manufacturing of cigarettes and filtered cigars for other established tobacco brands. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Mocksville, North Carolina.

Visit 22nd Century Group Inc Website

Investment Thesis

If 22nd Century Group can secure substantial non-dilutive financing or a strategic partnership to aggressively scale distribution of its FDA-authorized VLN products and Pinnacle Pure brands, leading to an annual VLN revenue run-rate exceeding $50M with sustainable positive gross margins within 3-5 years, then its unique regulatory moat could be monetized, potentially re-rating the common equity from its current distressed valuation to a speculative multi-bagger if preferred shareholder obligations can be managed. This is bullish because the market currently assigns negligible value to its common equity, despite holding a unique, high-barrier-to-entry regulatory asset.

Is XXII Stock Undervalued?

22nd Century Group Inc. (XXII) remains an extremely high-risk investment with virtually no clear path to 10x growth for common shareholders in its current state. The company continues to face dire financial health, as evidenced by Q1 2026 results reporting declining revenue (-31.1% YoY), a negative gross loss ($0.636M), and significant net ($3.019M) and operating ($3.039M) losses. Its cash position of $9.545M is precarious given its substantial cash burn. While the company's FDA MRTP authorization for Very Low Nicotine (VLN) tobacco products provides a unique regulatory moat, execution has been catastrophic. The announced 'Pinnacle Pure' expansion, while a positive operational step, is insufficient to counteract the fundamental financial distress, including a recent Chapter 11 filing, delisting, and preferred financing that subordinates common equity. The investment thesis is entirely dependent on an unprecedented operational and financial turnaround for a company currently fighting for survival, making substantial growth highly improbable.

Unlock the full AI analysis for XXII

Get the complete DVR score, risk analysis, and more

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

XXII Price Targets & Strategy

12-Month Target

$0.20

Bull Case

$1.50

Bear Case

$0.05

Valuation Basis

Highly speculative; base target reflects continued distress and dilution, with upside contingent on effective monetization of VLN MRTP and significant operational turnaround to reach a 0.5x P/S on hypothetical $20M VLN revenue run-rate.

Entry Strategy

Avoid for most investors. Extremely speculative entry for high-risk tolerance investors only, potentially below $0.50 if significant positive news emerges to signal a true turnaround.

Exit Strategy

Profit-taking at $1.00 (if turnaround momentum builds); Stop loss at $0.10 to limit further capital impairment if fundamental conditions continue to deteriorate.

Portfolio Allocation

0% for conservative/moderate; <0.1% for aggressive (purely speculative, high-risk capital only).

Price Targets & Strategy

Is XXII Financially Healthy?

Profitability

Gross Margin

-20.11%

Operating Margin

-76.48%

Net Margin

-25.34%

Return on Equity

-24.00%

Revenue Growth

-34.08%

EPS

$-192.26

Balance Sheet

Current Ratio

1.16

Quick Ratio

0.85

Debt/Equity

1.72

Cash & Equivalents

$9.54M

Cash Flow

EBITDA

-$2.60M

Other

Beta (Volatility)

0.60

Does XXII Have a Competitive Moat?

Moat Rating

🛡️ Narrow

Moat Trend

Eroding

Moat Sources

1 Identified

Intangible Assets/IP (FDA MRTP authorization)

The FDA MRTP authorization is a strong regulatory barrier, making it difficult for competitors to enter the very low nicotine tobacco market. However, 22nd Century Group's severe financial distress and poor execution are eroding its ability to monetize this moat, effectively weakening its competitive advantage.

Moat Erosion Risks

•Inability to raise capital to scale VLN production and distribution, leading to forfeiture of market opportunity.
•Increased competition from larger, better-capitalized tobacco companies developing their own reduced-nicotine products, potentially through acquisition if XXII further falters.

XXII Competitive Moat Analysis

XXII Market Intelligence

Sentiment & Insider Activity

Social Sentiment

Bearish (due to ongoing financial struggles, delisting, and severe losses impacting retail confidence)

Institutional Sentiment

Negative (no analyst coverage or institutional activity reported; prior preferred financing indicates institutional preference for senior positions)

Insider Activity (Form 4)

No Form 4 insider transactions were identifiable in the provided search results (last 90 days).

Options Flow

Normal options activity (no specific data provided, implying no unusual activity was detected by the search).

Earnings Intelligence

Next Earnings

Estimated early-August 2026 (for Q2 2026 results)

Surprise Probability

Low (given consistent losses and revenue decline, an upside surprise is highly improbable)

Historical Earnings Pattern

Likely volatile and negative reaction to earnings reports given the company's sustained financial distress and history of underperformance.

Key Metrics to Watch

VLN & Pinnacle branded product revenue (growth/decline vs. prior quarter)Gross margin performance (aiming for positive gross margin)Operating cash flow (path to reducing cash burn)Cash and cash equivalents (monitoring liquidity)

Competitive Position

Top Competitor

Altria Group, Inc. (MO) or British American Tobacco p.l.c. (BTI)

Market Share Trend

Losing (in overall tobacco market due to declining contract manufacturing); unknown/nascent in VLN specific market.

Valuation vs Peers

Not meaningfully comparable; XXII is distressed and loss-making, trading at negligible market cap whereas peers are large, profitable, dividend-paying companies.

Competitive Advantages

•Exclusive FDA MRTP authorization for VLN products (a significant regulatory barrier to entry for competitors)

Market Intelligence

What Could Drive XXII Stock Higher?

Near-Term (0-6 months)

•Q2 2026 earnings report (estimated early-August 2026): Positive surprise on VLN/Pinnacle revenue growth (>15% QoQ) and reduced cash burn.
•Pinnacle Pure distribution expansion to >5,000 retail outlets by end-2026: Confirmed success via significant sales volume reporting in next earnings.

Medium-Term (6-18 months)

•Major strategic partnership for VLN manufacturing or distribution (6-18 months): If a larger tobacco or consumer goods company partners to leverage the FDA MRTP, it could validate the market opportunity and provide much-needed capital/expertise.
•Demonstrated profitability in VLN segment (6-18 months): Consistent positive gross margins from VLN product sales exceeding $5M per quarter, signaling product viability.

Long-Term (18+ months)

•Successful and profitable full commercialization of VLN (18+ months): If VLN captures >1% of the reduced-risk tobacco market, potentially leading to $50M+ in annual revenue and positive EBITDA.
•Potential NASDAQ re-listing (18+ months): If the company achieves sustained profitability and meets minimum market capitalization and shareholder equity requirements, allowing for broader institutional investment.

Catalysts & Growth Drivers

What's the Bull Case for XXII?

✓
Quarterly VLN & Pinnacle brand revenue exceeding $10 million with positive gross margins.
✓
Company achieving positive operating cash flow for two consecutive quarters.
✓
Cash and cash equivalents consistently remaining above $15 million, indicating improved financial stability.
✓
Announcement of a strategic partnership or significant non-dilutive financing round.

Bull Case Analysis

Competing with XXII

See how 22nd Century Group Inc compares to related companies

Company	Market Cap	DVR Score	P/E	Revenue	Profit Margin	Rev Growth
22nd Century Group Inc XXII	$2.4M	1.5	—	$6.1M	-25.3%	-34.1%
Costco Wholesale Corp COST	—	0.7	—	—	—	—	Compare →
Coca-Cola Co KO	$339.2B	0.5	24.8	$48.9B	27.8%	5.1%	Compare →
PepsiCo Inc PEP	—	0.1	—	—	—	—	Compare →
Procter & Gamble Co PG	$341.2B	0.2	20.5	$84.3B	19.2%	3.3%	Compare →
Walmart Inc WMT	$972.0B	0.7	42.8	$713.2B	3.1%	5.9%	Compare →

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.

Analyze Any Stock →View Top 100 Deep Value Stocks →

How 22nd Century Group Inc Makes Money

22nd Century Group is a plant biotechnology company focused on developing and commercializing tobacco products with significantly reduced nicotine content, primarily through its FDA Modified Risk Tobacco Product (MRTP) authorized VLN® brand. The company also markets natural-style tobacco products under its Pinnacle brands and performs contract manufacturing for other tobacco companies. Their business model revolves around leveraging proprietary plant genetics to create products aimed at harm reduction within the tobacco industry, targeting consumers seeking lower nicotine alternatives.

Read Full Business Model Breakdown

FAQ

What is the DVR Score for 22nd Century Group Inc (XXII)?

As of June 2, 2026, 22nd Century Group Inc has a DVR Score of 1.5 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the market capitalization of 22nd Century Group Inc?

22nd Century Group Inc's market capitalization is approximately $2.4M. The company operates in the Consumer Defensive sector within the Tobacco industry.

What ticker symbol does 22nd Century Group Inc use?

XXII is the ticker symbol for 22nd Century Group Inc. The company trades on the NCM.

What is the risk level for XXII stock?

Our analysis rates 22nd Century Group Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

Is 22nd Century Group Inc's revenue growing?

22nd Century Group Inc has reported revenue growth of -34.1%. Revenue has been declining, which warrants closer examination.

Is XXII stock profitable?

22nd Century Group Inc has a profit margin of -25.3%. The company is currently unprofitable.

How often is the XXII DVR analysis updated?

Our AI-powered analysis of 22nd Century Group Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 2, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for XXII (22nd Century Group Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.